General
De novo molecular design in healthcare research
Research meeting with the Board of Directors on Wednesday 31th of January from 16:00-17:00 hrs on De novomolecular design in healthcare research. This meeting is of interest to all researchers interested in the application of experimental and computational technologies in drug discovery, vaccine development or gene therapy. Please feel free to share this invitation with members of you research group.
Programme:
New experimental and computational technologies are rapidly changing modern health care research, be it in drug discovery, vaccine development or gene therapy. In this session three researchers present their current work: how protein modelling helps to design new vaccines, how drug repurposing and gene editing are used to treat genetic metabolic disorders, and how neurodegenerative diseases are mitigated by restoring dopamine production. These projects have in common that they are based on a fundamental understanding of molecular functions and interactions, use advanced model systems, and exploit the power of AI and machine learning to define relevant biomarkers and endpoints. The combination of efficient model systems and computational methods allows us to effectively and rapidly design de novomolecular solutions, before the start of a (long, risky, expensive) process towards clinical application. At the end of this session, we would like to discuss what is needed to fully exploit these exciting opportunities in fundamental and translational research to benefit patients and society.
Moderation:
- Dr. Marit van Gils, Department of Medical Microbiology, Amsterdam UMC, Amsterdam Institute for Infection and Immunity
- Prof. dr. Clara van Karnebeek, Emma Center for Personalized Medicine, Amsterdam UMC, Amsterdam Institute for Gastro-Enterology Endocrinology and Metabolism & Amsterdam Reproduction and Development
- Prof. dr. Peter van Tienderen, dean Faculty of Science, University of Amsterdam
Speakers:
- Dr. Lars van der Heide, associate professor, Swammerdam Institute for Life Sciences, Faculty of Science, and Macrobian Biotech.
- Dr. Kwinten Sliepen, postdoctoral fellow, Department of Medical Microbiology, Amsterdam UMC, Amsterdam institute for Infection and Immunity
- Dr. Signe Mosegaard Nielsen, Laboratory for Genetic Metabolic Diseases, Amsterdam UMC, Amsterdam Institute for Gastro-Enterology Endocrinology and Metabolism & Amsterdam Cardiovascular Sciences
- Mr. Patrick Schultink, Father of 14-yeal old Abel with Gyrate Atrophy